Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:45:37.711Z.
Calculation as of: 2026-10-06T14:45:37.711Z.
Quote observation: 2026-10-06T14:44:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f6ebf84f3f464cb4543e326b3b96959337d3a5891063dc6ef63f2f1a4491a7a3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.46M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | $1.40M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.45M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.46M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | N/A | 341.73x | 341.73x | 341.73x |
| Genprex, Inc. (GNPX)vs › | $1.31M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 18.93x | 18.93x | 18.93x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
